Literature DB >> 11136258

Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies.

T W Chun1, J S Justement, S Moir, C W Hallahan, L A Ehler, S Liu, M McLaughlin, M Dybul, J M Mican, A S Fauci.   

Abstract

CD8+ T cell-mediated antiviral activity against HIV has been described consistently in infected individuals; however, the role of this activity in controlling replication of HIV in the latently infected, resting CD4+ T cell reservoir is unclear. By using an ex vivo system, we show that replication of HIV in this viral reservoir is effectively suppressed in coculture by autologous CD8+ T cells in long-term nonprogressors (LTNPs) and in patients whose viremia was controlled by highly active antiretroviral therapy (HAART), but not in therapy-naive patients who had substantial levels of plasma viremia. This antiviral activity was largely independent of cytotoxic CD8+ T lymphocytes (CTL). When the role of soluble CD8+ T cell-derived factors was examined, we found that CC-chemokines played a major role in inhibition of viral replication in the latent viral reservoir in some LTNPs and patients receiving HAART, but not in chronically infected patients who were not receiving antiretroviral therapy. Potent antiviral activity, independent of CC-chemokines, was found mainly in patients in whom HAART was initiated shortly after the acute phase of HIV infection. These results indicate that CD8(+) T cells provide potent suppressive activity against HIV replication in the latent viral reservoir via direct cellular contact in patients who are naturally LTNPs or in those who are treated with HAART. Furthermore, the profound antiviral activity exerted by non-CC-chemokine soluble factors in infected patients who began HAART early in HIV infection suggests that preservation of this HIV-suppressive mechanism by early initiation of therapy may play an important role in the containment of viral replication in infected patients following interruption of therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11136258      PMCID: PMC14577          DOI: 10.1073/pnas.98.1.253

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

1.  Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy.

Authors:  T W Chun; R T Davey; M Ostrowski; J Shawn Justement; D Engel; J I Mullins; A S Fauci
Journal:  Nat Med       Date:  2000-07       Impact factor: 53.440

2.  HIV-1 rebound after anti-retroviral therapy.

Authors:  D D Ho; L Zhang
Journal:  Nat Med       Date:  2000-07       Impact factor: 53.440

3.  Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression.

Authors:  H Hatano; S Vogel; C Yoder; J A Metcalf; R Dewar; R T Davey; M A Polis
Journal:  AIDS       Date:  2000-07-07       Impact factor: 4.177

4.  Re-emergence of HIV after stopping therapy.

Authors:  T W Chun; R T Davey; D Engel; H C Lane; A S Fauci
Journal:  Nature       Date:  1999-10-28       Impact factor: 49.962

5.  HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression.

Authors:  R T Davey; N Bhat; C Yoder; T W Chun; J A Metcalf; R Dewar; V Natarajan; R A Lempicki; J W Adelsberger; K D Miller; J A Kovacs; M A Polis; R E Walker; J Falloon; H Masur; D Gee; M Baseler; D S Dimitrov; A S Fauci; H C Lane
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

6.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

7.  A diffusible lymphokine produced by CD8+ T lymphocytes suppresses HIV replication.

Authors:  C M Walker; J A Levy
Journal:  Immunology       Date:  1989-04       Impact factor: 7.397

8.  CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication.

Authors:  C M Walker; D J Moody; D P Stites; J A Levy
Journal:  Science       Date:  1986-12-19       Impact factor: 47.728

9.  CD8+ T cell-mediated suppressive activity inhibits HIV-1 after virus entry with kinetics indicating effects on virus gene expression.

Authors:  G D Tomaras; S F Lacey; C B McDanal; G Ferrari; K J Weinhold; M L Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

10.  A cytotoxic T lymphocyte inhibits acquired immunodeficiency syndrome virus replication in peripheral blood lymphocytes.

Authors:  H Tsubota; C I Lord; D I Watkins; C Morimoto; N L Letvin
Journal:  J Exp Med       Date:  1989-04-01       Impact factor: 14.307

View more
  22 in total

Review 1.  Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward.

Authors:  Ume L Abbas; John W Mellors
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

2.  Interleukin-2 production by polyfunctional HIV-1-specific CD8 T cells is associated with enhanced viral suppression.

Authors:  Olusimidele T Akinsiku; Anju Bansal; Steffanie Sabbaj; Sonya L Heath; Paul A Goepfert
Journal:  J Acquir Immune Defic Syndr       Date:  2011-10-01       Impact factor: 3.731

3.  Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis.

Authors:  Julian J Lum; Oren J Cohen; Zilin Nie; Joel G Weaver; Timothy S Gomez; Xiao-Jian Yao; David Lynch; André A Pilon; Nanci Hawley; John E Kim; Zhaoxia Chen; Michael Montpetit; Jaime Sanchez-Dardon; Eric A Cohen; Andrew D Badley
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

4.  Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication.

Authors:  Stephanie A Freel; Ralph A Picking; Guido Ferrari; Haitao Ding; Christina Ochsenbauer; John C Kappes; Jennifer L Kirchherr; Kelly A Soderberg; Kent J Weinhold; Coleen K Cunningham; Thomas N Denny; John A Crump; Myron S Cohen; Andrew J McMichael; Barton F Haynes; Georgia D Tomaras
Journal:  J Virol       Date:  2012-04-18       Impact factor: 5.103

Review 5.  HIV and the chemokine system: 10 years later.

Authors:  Paolo Lusso
Journal:  EMBO J       Date:  2006-01-26       Impact factor: 11.598

Review 6.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

Review 7.  Kill: boosting HIV-specific immune responses.

Authors:  Lydie Trautmann
Journal:  Curr Opin HIV AIDS       Date:  2016-07       Impact factor: 4.283

8.  Slowly declining levels of viral RNA and DNA in DNA/recombinant modified vaccinia virus Ankara-vaccinated macaques with controlled simian-human immunodeficiency virus SHIV-89.6P challenges.

Authors:  Yuyang Tang; Francois Villinger; Silvija I Staprans; Rama Rao Amara; James M Smith; James G Herndon; Harriet L Robinson
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection.

Authors:  Sophie Reuse; Miriam Calao; Kabamba Kabeya; Allan Guiguen; Jean-Stéphane Gatot; Vincent Quivy; Caroline Vanhulle; Aurélia Lamine; Dolores Vaira; Dominique Demonte; Valérie Martinelli; Emmanuelle Veithen; Thomas Cherrier; Véronique Avettand; Solène Poutrel; Jacques Piette; Yvan de Launoit; Michel Moutschen; Arsène Burny; Christine Rouzioux; Stéphane De Wit; Georges Herbein; Olivier Rohr; Yves Collette; Olivier Lambotte; Nathan Clumeck; Carine Van Lint
Journal:  PLoS One       Date:  2009-06-30       Impact factor: 3.240

10.  Factors associated with HIV-1 proviral DNA loads in patients with undetectable plasma RNA load.

Authors:  Jun Yong Choi; Young Goo Song; Young Hwa Kim; Chang Oh Kim; Myung Soo Kim; Bum Sik Chin; Sang Hoon Han; Suk Hoon Choi; Han Sung Lee; Su Jin Jeong; Heekyoung Choi; June Myung Kim
Journal:  J Korean Med Sci       Date:  2009-02-28       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.